Zai Lab (Shanghai) Co., Ltd. — Biomedical Watch V2

Traitements4programmes

Essais2liés

Publications0liées

SourceDBlocale

Traitements

4

Molécule	Indication / population	Phase	Objectif	Pays	Résultat
Investigator's Choice of TherapyThe purpose of this study is to evaluate the efficacy and safety of ZL-1310 compared to Investigator's Choice Therapy in participants with relapsed Small Cell Lung Cancer.	Cancer	Phase 3	À vérifier	United States, Austria, Belgium, China, Czechia, France, Germany, Greece, …	À vérifier
ZL-1310The purpose of this study is to evaluate the efficacy and safety of ZL-1310 compared to Investigator's Choice Therapy in participants with relapsed Small Cell Lung Cancer.	Cancer	Phase 1	À vérifier	United States, China, Israel, Spain	À vérifier
ZL-1310The purpose of this study is to evaluate the efficacy and safety of ZL-1310 compared to Investigator's Choice Therapy in participants with relapsed Small Cell Lung Cancer.	Cancer	Phase 3	À vérifier	United States, Austria, Belgium, China, Czechia, France, Germany, Greece, Italy, Japan, Netherlands, Poland, Spain, Turkey (Türkiye), United Kingdom	À vérifier
ZL-1310The purpose of this study is to evaluate the efficacy and safety of ZL-1310 compared to Investigator's Choice Therapy in participants with relapsed Small Cell Lung Cancer.	Cancer	Phase 1	À vérifier	United States, China, Israel, Spain	À vérifier

Essais cliniques

2

Molécule	Indication / population	Phase	NCT	Titre	Statut
ZL-1310	Cancer	Phase 1	NCT06179069	A Study of ZL-1310 in Subjects With Small Cell Lung Cancer	RECRUITING
ZL-1310	Cancer	Phase 3	NCT07218146	A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)	RECRUITING

Publications

0

Molécule	Indication / population	Titre	Journal	Date
Aucune publication.